The US opioid epidemic: OxyContin, the Sackler family, and the public-health response

Intuition Beginner

In 1996 a pharmaceutical company called Purdue Pharma launched OxyContin, a sustained-release formulation of the opioid oxycodone. Purdue marketed it aggressively to doctors as safe and non-addictive, citing a five-sentence letter published in a 1980 medical journal that had observed few addiction cases among hospitalized short-term patients. That letter, later shown to be misleading, became the scientific fig leaf for a campaign that reshaped American pain medicine. Doctors prescribed OxyContin widely — for back pain, dental work, surgical recovery — and within a few years millions of Americans were physically dependent on a drug roughly as potent as heroin.

The crisis unfolded in three waves. The first wave (1999-2010) was driven by prescription opioids like OxyContin and Vicodin. The second wave (2010-2013) began when prescriptions were tightened and many users switched to street heroin. The third wave (2013 onward) arrived when illicit fentanyl — a synthetic opioid 50 to 100 times more potent than morphine — replaced heroin in much of the US drug supply. Each wave required a different public-health response: prescribing limits, then medication-assisted treatment, then naloxone distribution and harm reduction.

Between 1999 and 2021 about 645,000 Americans died of opioid overdose — more than all US combat deaths in World War II. By 2021 the annual toll reached roughly 80,000, exceeding car crashes and gun deaths combined. The Sackler family, who owned Purdue Pharma, became billionaires as the crisis spiraled and later settled with states for about 6 billion dollars. The opioid epidemic ranks among the worst man-made public-health disasters in US history.

Visual Beginner

The three waves of overdose mortality map onto a rising staircase, each step triggered by a different drug and demanding a different intervention. Wave 1 climbed on prescription pills; Wave 2 on heroin; Wave 3 on fentanyl. The response pyramid — naloxone at the base, medication-assisted treatment in the middle, addressing social determinants at the top — targets all three layers at once rather than any single rung.

The staircase shows why single interventions fail: restricting prescriptions alone pushed users toward heroin, and interdicting heroin opened the market to fentanyl. Each wave's drug was deadlier and cheaper than the last, which is why the death toll climbed rather than stabilizing after each crackdown.

Worked example Beginner

Consider the CDC's count of US opioid-overdose deaths across the three waves, drawn from the CDC WONDER multiple-cause-of-death database.

Wave 1 (1999-2010, prescription opioids). The age-adjusted death rate from prescription opioids roughly quadrupled, from about 4,000 deaths in 1999 to about 16,000 in 2010. Over the same period OxyContin sales grew from under 50 million dollars at the 1996 launch to over 3 billion dollars by 2010, and total US retail opioid prescribing peaked near 255 billion morphine-milligram-equivalents per year.

Wave 2 (2010-2013, heroin). As prescribing was tightened and OxyContin was reformulated to be harder to crush and inject, heroin overdose deaths roughly doubled, from about 3,000 in 2010 to about 8,000 in 2013. Users who could no longer obtain or abuse prescription opioids switched to street heroin, which was cheaper and increasingly supplied by cartels expanding across the Midwest and Appalachia.

Wave 3 (2013-present, illicit fentanyl). Deaths from synthetic opioids other than methadone — overwhelmingly fentanyl and its analogs — rose from about 3,000 in 2013 to about 71,000 in 2021. Fentanyl is cheap to synthesize from chemical precursors, 50 to 100 times more potent than morphine, and is typically mixed into heroin or pressed into counterfeit pills without the user's knowledge, making overdose unpredictable.

Total (1999-2021). Summed across the three waves, about 645,000 Americans died of opioid overdose. By 2021 the annual rate of about 80,000 deaths exceeded car-crash and gun deaths combined. Each wave's substitute drug was more potent and cheaper than the last.

What this tells us: the epidemic's lethality escalated with each wave because each substitute was more potent than the last, and because each single-prong response — prescribing limits, interdiction, criminalization — lagged the supply shift and did not address the coupled drivers of demand and harm.

Check your understanding Beginner

Formal definition Intermediate+

Definition (opioid). An opioid is any compound — endogenous (endorphin, enkephalin, dynorphin) or exogenous — that acts as an agonist at one or more of the three opioid receptor types $\mu$ (mu, MOR, encoded by $OPRM1$), $\kappa$ (kappa, KOR), and $\delta$ (delta, DOR). The $\mu$-opioid receptor mediates the principal therapeutic and adverse effects of medical opioids: analgesia, sedation, euphoria, and respiratory depression. The major medically used opioids — morphine, oxycodone, hydrocodone, codeine, fentanyl, methadone, buprenorphine — are $\mu$-agonists, with buprenorphine a partial agonist. Heroin (diacetylmorphine) is a $\mu$-agonist prodrug that crosses the blood-brain barrier more rapidly than morphine and is deacetylated in the brain to morphine and 6-monoacetylmorphine.

Definition (tolerance, physical dependence, addiction). These three states are distinct and historically conflated, with the conflation driving both over-prescribing and the under-treatment of legitimate pain.

• Tolerance — receptor downregulation and desensitisation: higher doses are required over time to achieve the same analgesic or euphoric effect. Tolerance develops to analgesia and euphoria but only partially to respiratory depression and to constipation, which is why the lethal dose does not rise in proportion to the therapeutic dose.
• Physical dependence — the adapted physiological state in which abrupt cessation produces a withdrawal syndrome (myalgia, nausea, diarrhoea, lacrimation, rhinorrhoea, piloerection, anxiety, dysphoria). Opioid withdrawal is severe but rarely lethal in adults.
• Addiction (opioid use disorder, OUD) — compulsive use despite harm, defined clinically by 11 DSM-5 criteria, with moderate-to-severe OUD diagnosed at 4 or more. OUD is a brain disorder involving mesolimbic dopaminergic dysregulation and persists long after physical dependence resolves.

Definition (the three waves of the US opioid epidemic). The CDC partitions US opioid-overdose mortality into three chronologically overlapping waves (CDC WONDER multiple-cause-of-death data).

• Wave 1 (1999-2010), prescription opioids. OxyContin (sustained-release oxycodone) and Vicodin (hydrocodone-acetaminophen) dominated. The age-adjusted death rate from prescription opioids roughly quadrupled.
• Wave 2 (2010-2013), heroin. As prescribing was tightened and OxyContin was reformulated as abuse-deterrent in 2010, the heroin death rate roughly doubled. Many users who could no longer obtain or abuse prescription opioids switched to street heroin.
• Wave 3 (2013-present), illicit fentanyl. Synthetic-opioid deaths (overwhelmingly fentanyl and analogs) rose more than twentyfold over the decade, reaching about 71,000 in 2021.

Definition (harm reduction and medication-assisted treatment).

• Naloxone (Narcan) — a competitive $\mu$-receptor antagonist that reverses opioid overdose by displacing the agonist from the receptor. It must be administered within minutes of onset; fentanyl's potency may require multiple doses.
• Medication-assisted treatment (MAT) — buprenorphine (a partial $\mu$-agonist with a ceiling on respiratory depression, allowing safer outpatient prescribing; SAMHSA deregulated office-based prescribing in 2023) or methadone (a full $\mu$-agonist, available only through federally licensed Opioid Treatment Programs). MAT approximately halves all-cause mortality in OUD patients (Sordo 2017).
• Syringe service programs — reduce HIV and HCV transmission without increasing drug use.
• Fentanyl test strips — allow users to detect fentanyl contamination in street drugs and adjust use accordingly.

Counterexamples to common slips Intermediate+

• "OxyContin caused all overdose deaths." No. Wave 3 deaths are almost entirely illicit fentanyl, which originates from overseas chemical precursors processed by clandestine laboratories, not from prescriptions. OxyContin drove Wave 1; the Wave 3 driver is a different supply chain entirely.
• "Addicts choose to use." No. OUD is a brain disorder with substantial genetic and environmental drivers. Compulsive use despite harm is a diagnostic criterion, not a voluntary behavior, and persists long after physical dependence resolves.
• "Naloxone encourages drug use." No. Multiple community studies (Walley 2013, BMJ) show no increase in opioid use when naloxone is distributed to communities and peers; overdose death rates fall.
• "Buprenorphine is substituting one addiction for another." No. Buprenorphine is a partial $\mu$-agonist that stabilises receptor occupancy with a ceiling on respiratory depression. It has a demonstrated all-cause mortality benefit.
• "The Sacklers alone caused the epidemic." Oversimplified. Many actors contributed: the FDA (approval without abuse-deterrent requirements), the Joint Commission (the pharmaceutical-funded "5th vital sign" campaign), the wholesale distributors (McKesson, Cardinal Health, AmerisourceBergen, who paid multi-billion-dollar penalties for ignoring suspicious-order reporting), prescribers, and the underlying despair documented by Case and Deaton.
• "We can arrest our way out." No. Drug Enforcement Administration interdiction has limited effect on a chemical that is cheap to synthesize from diverted precursors; criminalization worsens harm by pushing users toward more dangerous supply and discouraging help-seeking.

Key model: the syndemic of opioid overdose Intermediate+

The opioid epidemic is not a single epidemic with a single driver but a syndemic — a cluster of mutually reinforcing epidemics operating at biological, behavioural, and social levels. The term, introduced by Singer 2009, captures three observations: the three waves are coupled through substitution dynamics (restricting one supply shifts users to the next); the affected populations overlap with other epidemics (HIV and HCV from injection, depression, suicide, the broader "deaths of despair"); and addressing only one layer fails.

Definition (syndemic). A syndemic is the aggregation of two or more interacting epidemics in a population, where biological and social interactions between the epidemics worsen the prognosis of each.

The formal content of the syndemic claim for opioids is a compartmental-flow result. Let $D$ denote the total population seeking opioids (demand), $S\le D$ the number obtaining prescription opioids (supply), and $D-S$ the number using illicit opioids, taken to be fentanyl-dominated in Wave 3. Let ${\mu }_P$ and ${\mu }_F$ be the per-capita annual overdose-mortality rates in the prescription and fentanyl compartments, with ${\mu }_F>{\mu }_P$.

Key result: the supply-restriction paradox

Proposition (supply-restriction paradox). Under the compartmental model above, total overdose mortality is $M(S)={\mu }_{P}S+{\mu }_F(D-S)$, so $dM/dS=-({\mu }_F-{\mu }_P)<0$: reducing prescription supply $S$ increases total overdose mortality at the rate of ${\mu }_F-{\mu }_P$ additional deaths per displaced user, provided demand $D$ is unchanged.

Proof. By linearity of the mortality aggregation, $M(S)={\mu }_{P}S+{\mu }_F(D-S)={\mu }_{F}D-({\mu }_F-{\mu }_P)S$. Differentiating with respect to $S$ gives $dM/dS={\mu }_P-{\mu }_F=-({\mu }_F-{\mu }_P)$, which is strictly negative since ${\mu }_F>{\mu }_P$. Each unit reduction in $S$ transfers one user from the prescription compartment (mortality ${\mu }_P$) to the fentanyl compartment (mortality ${\mu }_F$), contributing the marginal excess risk ${\mu }_F-{\mu }_P>0$ to total mortality. The supply $S$ enters the mortality expression only through the difference ${\mu }_F-{\mu }_P$, which is unaffected by any demand-side intervention: $D$ is held fixed by the proposition's premise that the population seeking opioids is not reduced by the supply restriction. $\square$

The corollary is that interventions which reduce demand $D$ (MAT, which removes users from the opioid-seeking pool by stabilising them on buprenorphine or methadone), or which reduce ${\mu }_F$ (naloxone distribution, fentanyl test strips, supervised-consumption sites), or which reduce ${\mu }_P$ (prescription-monitoring programs) can each reduce $M$; reducing $S$ alone cannot. This is the formal content of the empirical observations in Van Zee 2009 and Kolodny 2015: waves 2 and 3 followed wave 1's prescribing crackdown, and each successive wave was more lethal than the last because the substitute drug had a higher per-user mortality rate.

Bridge. This result builds toward the multi-prong public-health framework surveyed in 35.06.01, and appears again in the harm-reduction principle of 35.02.05, where HIV prevention via needle exchange and pre-exposure prophylaxis relies on the same insight: reducing one harm without addressing coupled harms simply redirects mortality rather than reducing it. The foundational reason is that the epidemic is a flow network in which supply, demand, and lethality are distinct levers, and this is exactly the structure that identifies prescribing limits as a necessary-but-not-sufficient intervention: the bridge is between supply-side restriction (decreasing $S$) and demand-and-harm reduction (decreasing $D$ and ${\mu }_F$), and only the combined strategy generalises across all three waves.

Exercises Intermediate+

Advanced results Master

Result 1 (Porter-Jick 1980 — the five-sentence letter). The 1980 correspondence from Jane Porter and Hershel Jick in the New England Journal of Medicine ^{[PorterJick1980]} reported that of nearly 12,000 inpatients who received at least one narcotic dose at Boston City Hospital, only 4 with no prior addiction history developed documented addiction. The letter was five sentences long and concerned acute inpatient use. Leung and colleagues documented in a 2017 NEJM review that the letter was cited more than 600 times, with the rate of citations accelerating after 1995 (the OxyContin approval year), and that the large majority of citing articles used it as evidence that outpatient chronic opioid therapy was safe — a claim the letter neither studied nor supported.

Result 2 (Portenoy-Foley 1986 — the reassurance). Russell Portenoy and Kathleen Foley's 1986 paper in Pain ^{[PortenoyFoley1986]} described 38 patients with chronic non-cancer pain treated with sustained opioid therapy and reported that only 2 developed problematic behavior. The paper concluded that opioid therapy could be safe for selected non-cancer patients, explicitly hedging that the sample was small and selected. Purdue's marketing cited the Portenoy-Foley paper and the Porter-Jick letter together as the scientific basis for the below-one-percent addiction claim used to promote OxyContin after its 1996 launch.

Result 3 (Van Zee 2009 — the marketing analysis). Art Van Zee's 2009 analysis in the American Journal of Public Health ^[VanZee2009] reconstructed Purdue's OxyContin marketing campaign: between 1996 and 2002 the company funded more than 20,000 pain-education programs reaching tens of thousands of physicians, distributed the misleading below-one-percent addiction claim in promotional materials, and deployed a sales force whose bonuses were tied to volume. OxyContin sales grew from about 50 million dollars in 1996 to over 3 billion dollars by 2010. Van Zee argued that the marketing campaign was the principal driver of Wave 1 prescription-opioid mortality.

Result 4 (Kolodny 2015 — prescribing and mortality). Andrew Kolodny and colleagues' 2015 review in Public Health Reports ^{[Kolodny2015]} drew the state-level correlation between opioid prescribing rates and overdose mortality and argued that the epidemic was driven by overexposure to prescription opioids, not by an increase in pain prevalence or by a sudden epidemic of addiction. The paper framed opioid use disorder as a consequence of exposure in vulnerable individuals, not as a moral failing, and it argued for a public-health approach combining prescribing limits, expansion of medication-assisted treatment, and harm reduction rather than a criminal-justice approach.

Result 5 (Dowell-Haegerich-Chou 2016 — the CDC prescribing guideline). The 2016 CDC Guideline for Prescribing Opioids for Chronic Pain ^[CDC2016] recommended that clinicians prescribe the lowest effective dose, avoid doses above 50 morphine-milligram-equivalents per day without explicit justification, limit initial acute-pain prescriptions to 3 to 7 days, and use state prescription-drug-monitoring programs. The guideline was followed by a substantial decline in opioid prescribing after 2016, although its implementation was criticized for forcing some chronic-pain patients off effective therapy, and the CDC issued a clarification in 2022 emphasizing that rapid tapers were not recommended.

Result 6 (Case-Deaton 2015 — deaths of despair). Anne Case and Angus Deaton's 2015 paper in PNAS ^{[CaseDeaton2015]} documented that midlife mortality among white non-Hispanic Americans had risen since 1999, reversing decades of decline, driven by increases in drug overdose, alcoholic liver disease, and suicide — the three causes they labeled "deaths of despair." The paper reframed the opioid epidemic within a broader sociological pattern of cumulative disadvantage: declining real wages, labor-force exit, declining marriage rates, and deteriorating self-reported health among less-educated whites. The deaths-of-despair framework is the sociological complement to the pharmacological account: OxyContin was the match, but the underlying despair was the kindling.

Result 7 (Sordo 2017 — MAT mortality benefit). Sordo and colleagues' 2017 meta-analysis in BMJ ^[Sordo2017] pooled cohort studies of opioid-use-disorder patients on methadone or buprenorphine versus no medication and found that retention on either medication approximately halved all-cause mortality and overdose mortality. The pooled overdose mortality rate off medication was about 2.6 percent per year during the highest-risk period (the first 4 weeks after leaving treatment); on methadone or buprenorphine it was about 1.3 percent or lower. This is the empirical basis for the claim that MAT expansion is the single most effective clinical intervention for reducing opioid-overdose mortality.

Result 8 (Purdue bankruptcy and the Sackler settlement, 2019-2022). Massachusetts sued Purdue Pharma and the Sackler family in 2018; by 2019 Purdue faced approximately 2,600 lawsuits from state and local governments and filed for Chapter 11 bankruptcy. The first bankruptcy plan, confirmed in 2021, would have granted the Sacklers broad civil immunity over the objections of the US Department of Justice; the DOJ appealed and the plan was vacated. A revised plan, confirmed in 2023, provides approximately 6 billion dollars from the Sackler family to states and localities for opioid-abatement, dissolves Purdue, and reconstitutes its assets under a public-benefit company. The Sacklers were not individually criminally prosecuted, a point of sustained controversy.

Synthesis. The four decades from the 1980 Porter-Jick letter to the 2023 SAMHSA buprenorphine deregulation form the foundational reason the opioid epidemic is the canonical US public-health case study of the early twenty-first century. The central insight — that supply restriction without demand-and-harm reduction redirects mortality rather than reducing it — built toward the supply-restriction paradox formalized in the Key result, and appears again in the harm-reduction principle shared with HIV prevention in 35.02.05, where needle exchange and pre-exposure prophylaxis rely on the same principle that reducing one harm in a coupled network without addressing the others simply displaces deaths.

Putting these together with the Case-Deaton deaths-of-despair framework and the Sordo MAT mortality result, the bridge is between the pharmacology of $\mu$-receptor agonism and the sociology of cumulative disadvantage. This is exactly the structure that identifies the opioid epidemic as a syndemic rather than a drug problem: the pattern generalises to every coupled epidemic where biological, behavioural, and social drivers reinforce each other, from HIV-hepatitis-C coinfection to the stimulant-and-opioid polydrug overdoses emerging in the xylazine era, and the unifying public-health response — naloxone, MAT, harm reduction, and addressing social determinants simultaneously — is the operational consequence of treating the epidemic as a syndemic rather than a supply problem.

Full proof set Master

Proposition 1 (supply-restriction paradox, restated). Under the compartmental model with demand $D$, prescription supply $S$, and per-capita mortalities ${\mu }_P<{\mu }_F$, total mortality $M(S)={\mu }_{P}S+{\mu }_F(D-S)$ satisfies $dM/dS=-({\mu }_F-{\mu }_P)<0$.

Proof. Expanding: $M(S)={\mu }_{P}S+{\mu }_{F}D-{\mu }_{F}S={\mu }_{F}D+({\mu }_P-{\mu }_F)S$. Differentiating with respect to $S$: $dM/dS={\mu }_P-{\mu }_F$. Since ${\mu }_F>{\mu }_P$ by the empirical observation that fentanyl has a higher per-user overdose mortality than prescription opioids, $dM/dS<0$, meaning that reducing $S$ (restricting prescriptions) increases $M$ when demand $D$ is unchanged. The marginal excess mortality per displaced user is ${\mu }_F-{\mu }_P$, which is the difference in per-capita lethality between the destination and origin compartments. $\square$

Proposition 2 (MAT population-attributable mortality reduction). Let $N$ be the opioid-use-disorder population, $\mu$ the per-capita annual mortality off medication, and $\rho \in (0,1)$ the relative mortality reduction on medication-assisted treatment (Sordo 2017 estimates $\rho \approx 0.5$). If $r\in [0,1]$ is the fraction of the OUD population retained on MAT, the population-level annual mortality is $M(r)=N\mu (1-r\rho )$, giving a population-attributable mortality reduction of $r\rho$.

Proof. Partition the OUD population into the MAT-retained stratum (size $rN$, mortality $\mu (1-\rho )$) and the non-MAT stratum (size $(1-r)N$, mortality $\mu$). Aggregate:

$$M(r)=rN\cdot \mu (1-\rho )+(1-r)N\cdot \mu =N\mu [r(1-\rho )+(1-r)]=N\mu [r-r\rho +1-r]=N\mu (1-r\rho ).$$

The mortality reduction relative to the no-MAT baseline $N\mu$ is $1-(1-r\rho )=r\rho$. With $\rho \approx 0.5$, retaining 40 percent of the OUD population on MAT reduces population-level mortality by approximately 20 percent; universal retention would reduce it by approximately 50 percent. This is why MAT expansion is the single most cost-effective clinical intervention for reducing opioid-overdose mortality, and why the 2023 SAMHSA deregulation of buprenorphine prescribing is expected to save lives at the population level by raising $r$. $\square$

Proposition 3 (naloxone community-distribution effect). Suppose naloxone distribution to a community reduces the case-fatality rate of witnessed opioid overdose from $c_0$ to $c_1<c_0$ by enabling bystander reversal, while leaving the per-user overdose-event rate unchanged. Then the effective fentanyl-compartment mortality falls from ${\mu }_F$ to ${\mu }_F^{\prime }={\mu }_F\cdot (c_1/c_0)$, and the supply-restriction gradient softens from $-({\mu }_F-{\mu }_P)$ to $-({\mu }_F^{\prime }-{\mu }_P)$, reducing the marginal mortality cost of each displaced user.

Proof. Let the fentanyl per-capita overdose-event rate be ${\lambda }_F$ (events per user per year) and the case-fatality rate without naloxone be $c_0$, so ${\mu }_F={\lambda }_F{c}_0$. With community naloxone distribution the case-fatality rate falls to $c_1<c_0$ because bystanders administer naloxone before the overdose becomes fatal; the overdose-event rate ${\lambda }_F$ is empirically unchanged (Walley 2013 found no increase in use with naloxone distribution). Thus ${\mu }_F^{\prime }={\lambda }_F{c}_1={\mu }_F(c_1/c_0)<{\mu }_F$. The new supply-restriction gradient is $-({\mu }_F^{\prime }-{\mu }_P)$, which is smaller in absolute value than $-({\mu }_F-{\mu }_P)$ because ${\mu }_F^{\prime }<{\mu }_F$. In the limit of near-universal naloxone availability where $c_1/c_0\to 0$, the marginal cost of supply restriction approaches $-(-{\mu }_P)={\mu }_P>0$, meaning that prescription supply restriction would begin to reduce mortality rather than increase it, because both compartments would have comparably low lethality. This is the formal argument for combining naloxone distribution with any supply-side intervention. $\square$

Connections Master

• Public health, epidemiology, and health systems 35.06.01. This unit supplies the depth slice for the opioid chapter of the public-health survey, building on the survey's overview of epidemiological study designs, causal inference, and the Bradford Hill criteria for causation. The survey's framework for evidence-based public-health policy — combining randomized trials (HPTN 052 for HIV), observational cohort studies (the Case-Deaton mortality analysis), and causal-inference methods over state-level prescribing data — is exactly the toolkit used to establish the prescribing-mortality correlation in Kolodny 2015 and to motivate the CDC 2016 prescribing guideline. The syndemic concept and the supply-restriction paradox formalized here specialize the survey's general account of multi-prong public-health interventions.

• HIV/AIDS: retroviral biology, pathogenesis, and pandemic response 35.02.05. The HIV/AIDS and opioid epidemics share the defining structure of a harm-reduction public-health response: both were worsened by early policy failures (delayed ART rollout; over-prescribing of OxyContin) and both were eventually addressed by interventions that target coupled harms simultaneously — needle exchange and syringe-service programs reduce both HIV transmission and fatal overdose, naloxone distribution parallels pre-exposure prophylaxis as a population-level prevention tool, and the "treatment as prevention" logic of HIV U=U reappears in the MAT-retention mortality-reduction result of Sordo 2017. Injection opioid use is in fact the principal driver of heterosexual HIV transmission in several US regions, making the two epidemics biologically coupled as well as structurally parallel.

• Mental health: disorders, stigma, and treatment 35.05.01. Opioid use disorder is comorbid with depression, post-traumatic stress, and other substance-use disorders at rates of 40 to 60 percent, and the Case-Deaton "deaths of despair" framework explicitly locates the opioid epidemic within a cluster of rising midlife mortality from overdose, alcoholic liver disease, and suicide. The stigma attached to OUD parallels the stigma around severe mental illness examined in 35.05.01: both reduce help-seeking, both are worsened by criminalization, and both respond to the integration of pharmacotherapy with psychosocial treatment rather than to punishment. The neurobiology of addiction introduced there provides the mechanistic substrate for why MAT works and why criminalization alone fails.

• Cytochrome P450 pharmacogenomics: precision dosing and drug interactions 35.07.04. Most clinically used opioids are metabolised by cytochrome-P450 enzymes: oxycodone and hydrocodone by CYP3A4 and CYP2D6, fentanyl primarily by CYP3A4, methadone by CYP2B6 and CYP2D6, and buprenorphine by CYP3A4. Polymorphisms in these enzymes — particularly CYP2D6 poor-metabolizer and ultra-rapid-metabolizer phenotypes — produce multi-fold variation in opioid analgesic response and overdose risk between patients on the same dose, and CYP3A4 inhibition by drugs such as azole antifungals and macrolide antibiotics can precipitate fentanyl overdose. The precision-dosing framework of 35.07.04 is the pharmacogenomic substrate on which individual opioid response variation is layered.

Historical & philosophical context Master

Russell Portenoy and Kathleen Foley's 1986 paper in Pain ^{[PortenoyFoley1986]} argued that chronic opioid therapy was safe for selected non-cancer pain patients, citing in support a five-sentence 1980 NEJM correspondence from Porter and Jick ^{[PorterJick1980]} that had described fewer than one-percent addiction among short-term inpatient narcotic recipients. The Porter-Jick letter was a clinical observation in hospitalized patients, not a study of outpatient chronic use, yet over the following decade it was cited more than 600 times, with the citation rate accelerating after the 1995 FDA approval of OxyContin. Leung and colleagues' 2017 bibliometric analysis in NEJM documented that the large majority of citing articles used the letter as evidence that long-term outpatient opioid prescribing was safe — a claim it neither studied nor supported.

The Joint Commission's 1995-2000 campaign to make pain the "fifth vital sign," which received pharmaceutical-industry funding, institutionalized the expectation that clinicians treat pain scores aggressively. Purdue Pharma launched OxyContin in 1996 with a sales force that told physicians the Portenoy-Foley data showed addiction rates below one percent in chronic-pain patients. Van Zee's 2009 analysis in the American Journal of Public Health ^[VanZee2009] reconstructed the marketing: between 1996 and 2002 Purdue funded over 20,000 pain-education programs reaching tens of thousands of physicians and distributed the misleading below-one-percent claim in promotional materials. OxyContin sales grew from about 50 million dollars in 1996 to over 3 billion dollars by 2010.

Kolodny and colleagues' 2015 review in Public Health Reports ^{[Kolodny2015]} drew the state-level correlation between opioid prescribing rates and overdose mortality and argued that the epidemic was driven by overexposure to prescription opioids rather than by an increase in pain prevalence or a sudden surge of addiction. The CDC's 2016 prescribing guideline ^[CDC2016] recommended dose and duration limits; Case and Deaton's 2015 PNAS paper ^{[CaseDeaton2015]} framed the epidemic within the broader "deaths of despair" rise in midlife white mortality. Massachusetts sued Purdue in 2018; the company declared bankruptcy in 2019; the Sackler family settled with states for approximately 6 billion dollars in 2022-2023 without individual criminal prosecution.

Bibliography Master

@article{PorterJick1980,
  author = {Porter, J. and Jick, H.},
  title  = {Addiction rare in patients treated with narcotics},
  journal = {New England Journal of Medicine},
  volume = {302},
  number = {2},
  pages  = {123},
  year   = {1980},
  doi    = {10.1056/NEJM198001103020221},
}

@article{PortenoyFoley1986,
  author = {Portenoy, R. K. and Foley, K. M.},
  title  = {Chronic use of opioid analgesics in non-malignant pain:
            report of 38 cases},
  journal = {Pain},
  volume = {25},
  number = {2},
  pages  = {171--186},
  year   = {1986},
  doi    = {10.1016/0304-3959(86)90091-6},
}

@article{VanZee2009,
  author = {Van Zee, A.},
  title  = {The promotion and marketing of {OxyContin}: commercial
            triumph, public health tragedy},
  journal = {American Journal of Public Health},
  volume = {99},
  number = {2},
  pages  = {221--227},
  year   = {2009},
  doi    = {10.2105/AJPH.2007.131714},
}

@article{Kolodny2015,
  author = {Kolodny, A. and Courtwright, D. T. and Hwang, C. S. and
            Kreiner, P. and Eadie, J. L. and Clark, T. W. and
            Alexander, G. C.},
  title  = {The prescription opioid and heroin crisis: a public health
            approach to an epidemic of addiction},
  journal = {Public Health Reports},
  volume = {130},
  number = {2},
  pages  = {142--153},
  year   = {2015},
  doi    = {10.1177/003335491513000209},
}

@article{CDC2016,
  author = {Dowell, D. and Haegerich, T. M. and Chou, R.},
  title  = {{CDC} guideline for prescribing opioids for chronic pain
            --- {United States}, 2016},
  journal = {MMWR Recommendations and Reports},
  volume = {65},
  number = {RR-1},
  pages  = {1--49},
  year   = {2016},
  doi    = {10.15585/mmwr.rr6501e1},
}

@article{CaseDeaton2015,
  author = {Case, A. and Deaton, A.},
  title  = {Rising morbidity and mortality in midlife among white
            non-{H}ispanic Americans in the 21st century},
  journal = {Proceedings of the National Academy of Sciences},
  volume = {112},
  number = {49},
  pages  = {15078--15083},
  year   = {2015},
  doi    = {10.1073/pnas.1518393112},
}

@article{Sordo2017,
  author = {Sordo, L. and Barrio, G. and Bravo, M. J. and
            Indave, B. I. and Degenhardt, L. and Wiessing, L. and
            Ferri, M. and Pastor-Barriuso, R.},
  title  = {Mortality risk during and after opioid substitution
            treatment: systematic review and meta-analysis},
  journal = {BMJ},
  volume = {357},
  pages  = {j1550},
  year   = {2017},
  doi    = {10.1136/bmj.j1550},
}

@article{Walley2013,
  author = {Walley, A. Y. and Xuan, Z. and Hackman, H. H. and
            Quinn, E. and Doe-Simkins, M. and Sorensen-Alawad, A. and
            Ruiz, S. and Ozonoff, A.},
  title  = {Opioid overdose rates and implementation of overdose
            education and nasal naloxone distribution in {M}assachusetts:
            interrupted time series analysis},
  journal = {BMJ},
  volume = {346},
  pages  = {f174},
  year   = {2013},
  doi    = {10.1136/bmj.f174},
}

@article{Singer2009,
  author = {Singer, M.},
  title  = {Introduction to syndemics: a critical systems approach to
            public and community health},
  journal = {Jossey-Bass},
  year   = {2009},
}

@article{Leung2017,
  author = {Leung, P. T. M. and Macdonald, E. M. and Stanbrook, M. B. and
            Dhalla, I. A. and Juurlink, D. N.},
  title  = {A 1980 letter on the risk of opioid addiction},
  journal = {New England Journal of Medicine},
  volume = {376},
  number = {22},
  pages  = {2194--2195},
  year   = {2017},
  doi    = {10.1056/NEJMc1700150},
}

@article{Cicero2012,
  author = {Cicero, T. J. and Ellis, M. S. and Surratt, H. L.},
  title  = {Effect of abuse-deterrent formulation of {O}xy{C}ontin on
            opioid abuse results from a natural experiment},
  journal = {New England Journal of Medicine},
  volume = {367},
  number = {2},
  pages  = {187--189},
  year   = {2012},
  doi    = {10.1056/NEJMc1204141},
}

@book{Macy2017,
  author    = {Macy, Beth},
  title     = {Dopesick: Dealers, Doctors, and the Drug Company that
               Addicted America},
  publisher = {Little, Brown and Company},
  year      = {2017},
}

@book{Quinones2015,
  author    = {Qui{\~n}ones, Sam},
  title     = {Dreamland: The True Tale of America's Opiate Epidemic},
  publisher = {Bloomsbury Press},
  year      = {2015},
}